Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Iron chelation

John Porter
Antonios Kattamis, Maria Domenica Cappellini
, editors.
Maria Domenica Cappellini  1 , Dimitrios Farmakis  2 , John Porter  3 , Ali Taher  4
, editors.
In: 2021 Guidelines: For the Management of Transfusion Dependent Thalassaemia (TDT) [Internet]. 4th edition. Nicosia (Cyprus): Thalassaemia International Federation; 2023. CHAPTER 4.
Affiliations
Review

Iron chelation

John Porter.
No abstract available

PubMed Disclaimer

References

    1. Agarwal M.B., Gupte S.S., Viswanathan C., Vasandani D., et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. British Journal of Haematology. [Online] 1992;82(2):460–466. doi: 10.1111/j.1365-2141.1992.tb06445.x. Available from: doi: - DOI - PubMed
    1. Aldouri M.A., Wonke B., Hoffbrand A.V., Flynn D.M., et al. High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematologica. [Online] 1990;84(3):113–117. doi: 10.1159/000205046. Available from: doi: - DOI - PubMed
    1. Anderson L.J., Westwood M.A., Holden S., Davis B., et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. British Journal of Haematology. [Online] 2004;127(3):348–355. Available from: doi: https://doi.org/10.1111/j.1365-2141.2004.05202.x. - DOI - PubMed
    1. Aydinok Y., Evans P., Terzi A., Cetiner N., et al. Randomised Prospective Evaluation of Iron Balance, Chelation Efficiency, Urine Excretion and NTBI Progression with Deferiprone (DFP) or Deferoxamine (DFO) Monotherapy or with Combined DFP Plus DFO. Blood. [Online] 2005;106(11):2698–2698. doi: 10.1182/blood.V106.11.2698.2698. Available from: doi: - DOI
    1. Aydinok Y., Kattamis A., Cappellini M.D., El-Beshlawy A., et al. Deferasirox– Deferoxamine Combination Therapy Reduces Cardiac Iron With Rapid Liver Iron Removal In Patients With Severe Transfusional Iron Overload (HYPERION) Blood. [Online] 2013;122(21):2257–2257. doi: 10.1182/blood.V122.21.2257.2257. Available from: doi: - DOI